Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:FRX NASDAQ:IPA TSE:ITH NASDAQ:MDNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsIPAImmunoPrecise Antibodies$1.79-7.3%$0.90$0.27▼$2.32$81.91M0.442.61 million shs321,937 shsITHInternational Tower Hill MinesC$1.39-0.7%C$1.21C$0.57▼C$1.55C$195.15M1.1732,234 shs9,900 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies+6.04%+0.52%+127.06%+340.74%+101.04%ITHInternational Tower Hill Mines-4.76%+7.69%+16.67%+53.85%+105.88%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies3.013 of 5 stars3.55.00.00.03.20.00.6ITHInternational Tower Hill MinesN/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFRXForest Road Acquisition 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.00123.46% UpsideITHInternational Tower Hill Mines 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/AIPAImmunoPrecise Antibodies$18.16M4.51N/AN/A$0.93 per share1.92ITHInternational Tower Hill MinesN/AN/AC$0.06 per share22.50C$0.29 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-190.76%-88.87%-49.26%7/17/2025 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ALatest MDNA, FRX, ITH, and IPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFRXForest Road AcquisitionN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFRXForest Road AcquisitionN/A0.370.37IPAImmunoPrecise Antibodies0.452.322.11ITHInternational Tower Hill MinesN/A10.3730.48MDNAMedicenna TherapeuticsN/A9.579.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFRXForest Road AcquisitionN/AIPAImmunoPrecise Antibodies6.70%ITHInternational Tower Hill Mines71.80%MDNAMedicenna Therapeutics12.38%Insider OwnershipCompanyInsider OwnershipFRXForest Road AcquisitionN/AIPAImmunoPrecise Antibodies6.83%ITHInternational Tower Hill Mines0.51%MDNAMedicenna Therapeutics33.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionableIPAImmunoPrecise Antibodies8045.76 million42.64 millionNot OptionableITHInternational Tower Hill Mines220140.40 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableMDNA, FRX, ITH, and IPA HeadlinesRecent News About These CompaniesMedicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational HighlightsJune 26, 2025 | globenewswire.comMedicenna Therapeutics With Founder, Chairman, President & CEO, Dr. Fahar MerchantMay 14, 2025 | msn.comMedicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 22, 2025 | markets.businessinsider.comMedicenna Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (MDNA)February 23, 2025 | theglobeandmail.comMedicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025February 5, 2025 | globenewswire.comThese TSX stocks saw more gains in 2024 than all the others, so farDecember 27, 2024 | msn.comMedicenna’s MDNA11 Shows Promise in Cancer TreatmentDecember 13, 2024 | tipranks.comMedicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)December 13, 2024 | globenewswire.comMedicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 StudyDecember 5, 2024 | globenewswire.comUpdated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge ConferenceNovember 27, 2024 | financialpost.comFMedicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)November 25, 2024 | finance.yahoo.comMedicenna Showcases Promising Results and Strong FinancialsNovember 16, 2024 | markets.businessinsider.comMedicenna to Present Innovative Cancer Data at ConferencesNovember 13, 2024 | markets.businessinsider.comMedicenna announces single-agent activity of MDNA11 from dose expansion cohortNovember 11, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Buy Rating for Medicenna Therapeutics’ MDNA11November 11, 2024 | markets.businessinsider.comMedicenna Announces Breakthroughs in Cancer TreatmentNovember 9, 2024 | markets.businessinsider.comMedicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 4, 2024 | markets.businessinsider.com3 TSX Growth Stocks To Watch With Up To 39% Insider OwnershipSeptember 24, 2024 | finance.yahoo.comMedicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy ConferenceAugust 27, 2024 | finance.yahoo.com3 Growth Stocks On The TSX With Insider Ownership Up To 21%August 16, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI Spending3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeDon’t Miss These 2 Small Quantum Stocks Poised to PopBy Gabriel Osorio-Mazilli | June 24, 2025View Don’t Miss These 2 Small Quantum Stocks Poised to Pop3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedPalantir’s Revenue Surge to $1B: Growth vs. ValuationBy Chris Markoch | July 9, 2025View Palantir’s Revenue Surge to $1B: Growth vs. ValuationMDNA, FRX, ITH, and IPA Company DescriptionsForest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.ImmunoPrecise Antibodies NASDAQ:IPA$1.79 -0.14 (-7.25%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.International Tower Hill Mines TSE:ITHC$1.39 -0.01 (-0.71%) As of 09:34 AM EasternInternational Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an advanced stage exploration project namely the Livengood Gold Project. It is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska mental health trust, a number of smaller private mineral leases, Alaska state mining claims purchased or located by the company and patented ground held by the company.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
